Mary Mosher

Array ( [id] => 20577288 [patent_doc_number] => 12569523 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-10 [patent_title] => Engineered therapeutic probiotic system and method [patent_app_type] => utility [patent_app_number] => 18/432028 [patent_app_country] => US [patent_app_date] => 2024-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 62 [patent_no_of_words] => 8045 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18432028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657703 [patent_doc_number] => 20230303649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 17/861180 [patent_app_country] => US [patent_app_date] => 2022-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17861180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790502 [patent_doc_number] => 20220249593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => Materials and Methods for Treatment of Inflammation [patent_app_type] => utility [patent_app_number] => 17/725943 [patent_app_country] => US [patent_app_date] => 2022-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17725943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18168207 [patent_doc_number] => 20230034817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => RECOMBINANT AAV FOR TREATMENT OF NEURAL DISEASE [patent_app_type] => utility [patent_app_number] => 17/717858 [patent_app_country] => US [patent_app_date] => 2022-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17717858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18075947 [patent_doc_number] => 20220401559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/716248 [patent_app_country] => US [patent_app_date] => 2022-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17716248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17719148 [patent_doc_number] => 20220211867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => NANOPARTICLE FOR SPECIFICALLY HYDROLYZING TEMPLATE PROTEIN MOLECULE, AND PREPARATION AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/703946 [patent_app_country] => US [patent_app_date] => 2022-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17703946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426882 [patent_doc_number] => 20220054590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => PROTOXIN-II VARIANTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/397586 [patent_app_country] => US [patent_app_date] => 2021-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17397586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228624 [patent_doc_number] => 20210355180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => ALZHEIMER ABETA PEPTIDE BINDING POLYPEPTIDE [patent_app_type] => utility [patent_app_number] => 17/382466 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17382466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356810 [patent_doc_number] => 20220017606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => SARS-COV-2(SARS2, COVID-19) ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/381154 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17381154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20466608 [patent_doc_number] => 12522641 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Targeted mutant interferon-gamma and uses thereof [patent_app_type] => utility [patent_app_number] => 17/366343 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 25 [patent_no_of_words] => 42687 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505186 [patent_doc_number] => 20220098288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => METHODS OF TREATING ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/330898 [patent_app_country] => US [patent_app_date] => 2021-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42201 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318305 [patent_doc_number] => 20240239847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => PROTEINACEOUS PARTICLE [patent_app_type] => utility [patent_app_number] => 17/919756 [patent_app_country] => US [patent_app_date] => 2021-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25435 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17762676 [patent_doc_number] => 20220236288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => DETECTION OF NEURAL-DERIVED DEBRIS IN RECIRCULATING PHAGOCYTES [patent_app_type] => utility [patent_app_number] => 17/228416 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17228416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18351395 [patent_doc_number] => 20230139506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => HETEROCLITIC CANCER VACCINES [patent_app_type] => utility [patent_app_number] => 17/912461 [patent_app_country] => US [patent_app_date] => 2021-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17912461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18308185 [patent_doc_number] => 20230112085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => ANTI-B7-H4 CONSTRUCTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/796152 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20437491 [patent_doc_number] => 12508312 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-30 [patent_title] => Chimeric antigen receptor targeting CLL1 and use thereof [patent_app_type] => utility [patent_app_number] => 17/612212 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 2099 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17612212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082105 [patent_doc_number] => 20210277111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => LINGO-1 ANTAGONISTS AND USES FOR TREATMENT OF DEMYELINATING DISORDERS [patent_app_type] => utility [patent_app_number] => 17/127324 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57537 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18160422 [patent_doc_number] => 20230027014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => THERAPEUTIC COMPOSITIONS COMPRISING AN AMYLOID BETA ANTIBODY OR VACCINE FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 17/784585 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14727 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17784585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830845 [patent_doc_number] => 20230399370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => METHODS OF TREATING GLIOBLASTOMA [patent_app_type] => utility [patent_app_number] => 17/778522 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45495 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140176 [patent_doc_number] => 20210308187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA [patent_app_type] => utility [patent_app_number] => 17/096901 [patent_app_country] => US [patent_app_date] => 2020-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096901 [rel_patent_id] =>[rel_patent_doc_number] =>)